Hologic
During its annual strategic planning, the firm identified its expanding base of MDx instruments as an essential driver of increasing revenues.
Hologic Q3 Revenues Rise 42 Percent Despite Lower Demand for SARS-CoV-2 MDx Assays
The company posted a 25 percent revenue growth in its diagnostics business but saw lower demand for its Panther and Panther Fusion SARS-CoV-2 tests.
Hologic Obtains CE Mark for Use of Saliva With SARS-CoV-2 Molecular Test
The firm noted that saliva as an alternative to other types of specimens should help facilitate screening in schools, workplaces, and other settings.
There were 39 total mergers and acquisitions in the first six months of 2021, with two deals topping out over $1 billion.
Hologic Upgraded to Outperform by Evercore ISI
Investors are refocusing on Hologic's base business given an anticipated major cut to COVID-19 industry testing revenues in fiscal year 2022, according to Evercore.
Apr 30, 2021